Attached files

file filename
10-K - FORM 10-K - SLR Senior Investment Corp.d138521d10k.htm
EX-11.1 - EX-11.1 - SLR Senior Investment Corp.d138521dex111.htm
EX-31.1 - EX-31.1 - SLR Senior Investment Corp.d138521dex311.htm
EX-32.2 - EX-32.2 - SLR Senior Investment Corp.d138521dex322.htm
EX-31.2 - EX-31.2 - SLR Senior Investment Corp.d138521dex312.htm
EX-32.1 - EX-32.1 - SLR Senior Investment Corp.d138521dex321.htm
EX-21.1 - EX-21.1 - SLR Senior Investment Corp.d138521dex211.htm
Table of Contents

Exhibit 99.1

Gemino Healthcare Finance, LLC

and Subsidiary

Consolidated Financial Statements

December 31, 2015 and 2014


Table of Contents

Gemino Healthcare Finance, LLC and Subsidiary

 

Table of Contents

December 31, 2015 and 2014

 

     Page  

Independent Auditors’ Report

     1   

Consolidated Financial Statements

  

Consolidated Balance Sheet

     3   

Consolidated Statement of Operations

     4   

Consolidated Statement of Changes in Members’ Equity

     5   

Consolidated Statement of Cash Flows

     6   

Notes to Consolidated Financial Statements

     7   


Table of Contents
     

LOGO

 

     

Baker Tilly Virchow Krause, LLP

1650 Market St, Ste 4500

Philadelphia, PA 19103-7341

tel 215 972 0701

tel 800 267 9405

fax 888 264 9617

bakertilly.com

Independent Auditors’ Report

Board of Managers

Gemino Healthcare Finance, LLC

We have audited the accompanying consolidated financial statements of Gemino Healthcare Finance, LLC and Subsidiary, which comprise the consolidated balance sheet as of December 31, 2015 and 2014, and the related consolidated statements of operations, changes in members’ equity, and cash flows for the years then ended, and the related notes to the financial statements.

Management’s Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors’ Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity’s preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

 

LOGO   1   An Affirmative Action Equal Opportunity Employer


Table of Contents

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Gemino Healthcare Finance, LLC and Subsidiary as of December 31, 2015 and 2014, and the results of their operations and their cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

 

LOGO

Philadelphia, Pennsylvania

February 12, 2016

 

2


Table of Contents

Gemino Healthcare Finance, LLC and Subsidiary

 

Consolidated Balance Sheet

Years Ended December 31, 2015 and 2014

 

     2015     2014  
Assets     

Assets

    

Cash and cash equivalents

   $ 6,751,322      $ 6,339,962   

Loans receivable, net of allowance of $1,194,676 and $1,147,891, respectively

     116,689,953        112,202,058   

Accrued interest receivable

     902,137        884,351   

Deferred financing costs, net

     741,256        1,010,803   

Intangible asset—trade name

     2,800,000        2,800,000   

Goodwill

     5,663,531        5,663,531   

Other assets

     103,055        83,937   

Furniture and equipment, net

     26,588        39,222   
  

 

 

   

 

 

 

Total assets

   $ 133,677,842      $ 129,023,864   
  

 

 

   

 

 

 
Liabilities and Members’ Equity     

Liabilities

    

Advances due under credit facility

   $ 98,500,000      $ 95,000,000   

Accrued dividend payable

     558,187        466,734   

Accounts payable and accrued expenses

     1,997,910        1,239,197   
  

 

 

   

 

 

 

Total liabilities

     101,056,097        96,705,931   
  

 

 

   

 

 

 

Members’ Equity

    

Units, $1,000 par value, issued and outstanding 34,843 and 34,711, respectively

     33,867,146        33,725,600   

Retained deficit

     (1,245,401     (1,407,667
  

 

 

   

 

 

 

Total members’ equity

     32,621,745        32,317,933   
  

 

 

   

 

 

 

Total liabilities and members’ equity

   $ 133,677,842      $ 129,023,864   
  

 

 

   

 

 

 

See notes to consolidated financial statements

 

3


Table of Contents

Gemino Healthcare Finance, LLC and Subsidiary

 

Consolidated Statement of Operations

Years Ended December 31, 2015 and 2014

 

     2015     2014  

Interest Income

    

Interest income on loans

   $ 8,737,635      $ 8,204,737   

Interest expense

     (3,148,749     (2,839,139
  

 

 

   

 

 

 

Net interest income

     5,588,886        5,365,598   

Provision for Loan Losses

     (44,558     (566,397
  

 

 

   

 

 

 

Net interest income after provision for loan losses

     5,544,328        4,799,201   

Other Income

     3,636,566        2,701,518   

General and Administrative Expenses

     (5,299,772     (4,511,203
  

 

 

   

 

 

 

Net income

   $ 3,881,122      $ 2,989,516   
  

 

 

   

 

 

 

See notes to consolidated financial statements

 

4


Table of Contents

Gemino Healthcare Finance, LLC and Subsidiary

 

Consolidated Statement of Changes in Members’ Equity

Years Ended December 31, 2015 and 2014

 

Balance at December 31, 2013

   $ 32,432,747   

Additional capital contributions

     350,293   

Dividends declared

     (3,454,623

Net income

     2,989,516   
  

 

 

 

Balance at December 31, 2014

     32,317,933   

Additional capital contributions

     141,546   

Dividends declared

     (3,718,856

Net income

     3,881,122   
  

 

 

 

Balance at December 31, 2015

   $ 32,621,745   
  

 

 

 

See notes to consolidated financial statements

 

5


Table of Contents

Gemino Healthcare Finance, LLC and Subsidiary

 

Consolidated Statement of Cash Flows

Years Ended December 31, 2015 and 2014

 

     2015     2014  

Cash Flows from Operating Activities

    

Net income

   $ 3,881,122      $ 2,989,516   

Adjustments to reconcile net income to net cash provided by operating activities:

    

Depreciation

     27,657        27,576   

Amortization of discount on loans

     (23,698     (45,766

Amortization of deferred origination fees and costs

     (367,108     (164,792

Amortization of deferred financing costs

     269,547        255,725   

Provision and recoveries for loan losses

     46,785        566,397   

Changes in assets and liabilities:

    

Increase in accrued interest receivable

     (17,786     (99,672

(Increase) decrease in other assets

     (19,118     4,362   

Increase in deferred origination fees and costs, net

     516,855        518,225   

Increase in accounts payable and accrued expenses

     758,713        5,032   
  

 

 

   

 

 

 

Net cash provided by operating activities

     5,072,969        4,056,603   
  

 

 

   

 

 

 

Cash Flows from Investing Activities

    

Increase in loans receivable, net

     (4,660,729     (18,178,559

Purchase of furniture and equipment

     (15,023     (10,514
  

 

 

   

 

 

 

Net cash used in investing activities

     (4,675,752     (18,189,073
  

 

 

   

 

 

 

Cash Flows from Financing Activities

    

Net proceeds from credit facility

     3,500,000        12,000,000   

Financing costs paid and deferred for credit facility

     —          (173,212

Dividends paid

     (3,627,403     (3,404,354

Proceeds from contributed capital

     141,546        350,293   
  

 

 

   

 

 

 

Net cash provided by financing activities

     14,143        8,772,727   
  

 

 

   

 

 

 

Net increase (decrease) in cash and cash equivalents

     411,360        (5,359,743

Cash and Cash Equivalents, Beginning

     6,339,962        11,699,705   
  

 

 

   

 

 

 

Cash and Cash Equivalents, Ending

   $ 6,751,322      $ 6,339,962   
  

 

 

   

 

 

 

Supplemental Disclosure of Cash Flow Information

    

Interest paid

   $ 2,867,907      $ 2,720,187   
  

 

 

   

 

 

 

See notes to consolidated financial statements

 

6


Table of Contents

Gemino Healthcare Finance, LLC and Subsidiary

 

Notes to Consolidated Financial Statements

December 31, 2015 and 2014

 

1. Description of Business

Gemino Healthcare Finance, LLC (“Gemino”), a Delaware limited liability company formed in December 2006, is a commercial finance company that originates, underwrites, and manages primarily secured, asset-based loans for small and mid-sized companies operating across the U.S. in the healthcare industry. Gemino’s loans are primarily in the form of revolving lines of credit, secured by accounts receivable of the borrowers. The accounts receivable serving as collateral are primarily third party obligations from government payers, such as Medicare or Medicaid, and commercial insurers.

In certain cases, Gemino may provide senior term loan financing to qualified borrowers in addition to a revolving line of credit. Senior term loans are typically secured by accounts receivable, all other assets of the borrowers and a pledge of the stock of the borrowers.

Gemino Healthcare Funding, LLC (“Gemino Funding”), is a wholly-owned special purpose limited liability company, that purchases and holds certain eligible loans and related property from Gemino.

Pursuant to a definitive agreement dated September 30, 2013 (Acquisition Date), Solar Senior Capital Ltd., a Maryland corporation (“Solar”), acquired a controlling interest in Gemino. Gemino Management Investment, LLC (“GMI”), whose members include certain management employees of Gemino and who had an interest in Gemino before the transaction, co-invested in the transaction.

On December 31, 2013, Solar contributed all of its limited liability company interests in Gemino to Gemino Senior Secured Healthcare LLC (“Gemino Senior”), a holding company that was formed as a limited liability company under the laws of the State of Delaware in December 2013 for the purpose of holding the controlling interest of Gemino. Solar is the sole member of Gemino Senior. This change in legal ownership had no accounting or reporting impact on Gemino.

 

2. Summary of Significant Accounting Policies

Principles of Consolidation

The consolidated financial statements include the accounts of Gemino and Gemino Funding (collectively, the “Company”). All significant intercompany balances have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and to report amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. The allowance for loan loss represents an estimate that is particularly susceptible to material change.

Cash and Cash Equivalents

Cash equivalents consist of short-term highly liquid investments with original maturities of three months or less.

Loans Receivable and Income Recognition

Loans receivable that management has the intent and ability to hold for the foreseeable future or until maturity or payoff are reported at their outstanding unpaid principal balances less the allowance for loan loss and any deferred fees or costs.

 

7


Table of Contents

Gemino Healthcare Finance, LLC and Subsidiary

 

Notes to Consolidated Financial Statements

December 31, 2015 and 2014

 

Commitment terms of the Company’s financing agreements generally range from two to five years with interest charged on a floating rate basis. Funding under revolving loan commitments is subject to the Company’s estimation of the accounts receivable pledged as collateral.

Income on loans receivable is recognized using the simple interest method. The accrual of interest on loans is discontinued at the time the loan is 90 days delinquent unless the loan is well secured and/or in the process of collection. Typically, loans are placed on non-accrual or charged off at an earlier date if collection of principal or interest is considered doubtful. When a loan is placed on non-accrual status, all interest previously accrued, but not collected, is reversed against current interest income and all future proceeds received will generally be applied against principal or interest, in the judgment of management. Loans are returned to accrual status when all principal and interest amounts contractually due are reasonably assured.

Revolving loan origination fees and costs are deferred and amortized on a straight-line basis over the terms of the related loan commitments as an adjustment to interest income on loans. Term loan origination fees are deferred and amortized using either the effective interest method or the straight-line method over the life of the loan. The straight-line method may be used for term loan facilities when it approximates the effective interest method. Other fees, such as collateral monitoring fees, unused balance fees and collateral examination fees, are recognized when the services are provided. Termination fees are recognized when a loan is terminated. These other fees are included in other income.

Impaired Loans

A loan is considered impaired when, based on current information and events, it is probable that the Company will be unable to collect all amounts due in accordance with the contractual terms of the loan agreement. Loans are evaluated for impairment by the Company based on an ongoing analysis of each borrower’s repayment capacity, the value of the collateral support and the strength of any guarantees. Loans identified as impaired are further evaluated to determine the estimated extent of impairment.

Allowance for Loan Loss

The allowance for loan loss represents the Company’s recognition of the assumed risks of extending credit. The allowance is maintained at a level considered adequate to provide for probable losses inherent in the loan portfolio. Management establishes a general portfolio reserve for unimpaired loans based on various factors including historical loss experience, the overall credit quality of the loan portfolio, economic trends and conditions and the regulatory environment.

The overall credit quality of the Company’s borrowers is reflected in the individual and weighted average credit risk ratings of the loans in the portfolio. Credit risk ratings for each borrower are established based on a number of qualitative and quantitative factors including an assessment of management and strategy, historical and projected repayment capacity, collateral coverage and performance, financial condition and sponsorship, strength of guarantees and any contingencies.

Specific allowances for loan losses on impaired loans are typically measured based on a comparison of the recorded carrying value of the loan to the present value of the loan’s expected cash flow using the loan’s effective interest rate, the loan’s estimated market price or the estimated fair value of the underlying collateral, if the loan is collateral-dependent combined with the strength of any guarantee arrangements. Specific allowances are recorded when the discounted cash flows, collateral value, or aggregate market price of the impaired loan is lower than the carrying value of that loan.

 

8


Table of Contents

Gemino Healthcare Finance, LLC and Subsidiary

 

Notes to Consolidated Financial Statements

December 31, 2015 and 2014

 

Loans are charged off when collection is sufficiently questionable and when the Company can no longer justify maintaining the loan as an asset on the balance sheet. Loans qualify for charge off when, after thorough analysis, all possible sources of collection are determined to be insufficient to repay the loan. These include impairment of potential future cash flow, value of collateral and/or financial strength of guarantors. Recoveries of previous charge-offs are recorded when received.

Goodwill and Intangible Asset

Goodwill represents the excess of consideration paid for an acquired business over the fair value of the related assets acquired and liabilities assumed. Intangible asset—trade name has an indefinite life. Goodwill and intangible asset—trade name arose from the acquisition of the Company on September 30, 2013 (Note 1). The Company is required to assess its goodwill and indefinite-lived intangible asset for impairment annually, or more frequently if events or changes in circumstances indicate impairment may have occurred.

The Company assesses its indefinite-lived intangible asset for impairment by comparing the carrying value of the asset to its fair value, and assesses goodwill for impairment by comparing the carrying value of the Company to its fair value. The fair value of intangible asset—trade name is estimated using the relief from royalty method, which is an income approach based on the present value of royalties the Company would theoretically have to pay to license the trade name from a third party. The fair value of the Company is estimated using a weighted average amount of the present value of expected future cash flows and the adjusted market multiples of comparable companies. If the fair value is less than the carrying value, an impairment loss would be recorded. For the years ended December 31, 2015 and 2014, there were no impairments.

Furniture and Equipment

Furniture and equipment are recorded at cost, and are depreciated on a straight-line basis over their estimated useful lives ranging from three to five years.

Deferred Financing Costs

Deferred financing costs represent capitalized expenses incurred with debt financing transactions. The Company incurred and capitalized $173,212 of financing costs in 2014, in connection with its credit facility (Note 6). These costs are being amortized on a straight-line basis over the life of the agreement as an adjustment to interest expense.

Income Taxes

The Company is not subject to federal or state income taxes. Members of the Company have elected to report the taxable income or loss on their individual tax returns. Accordingly, no provision for income taxes has been recorded in the accompanying consolidated financial statements.

The Company applies authoritative guidance relating to the accounting for uncertain tax positions. Accordingly, a provision for uncertain tax positions and related penalties and interest is recognized when it is more-likely-than-not, based on the technical merits, that the tax position will be realized or sustained upon examination. The term more-likely-than-not means a likelihood or more than 50%. A tax position that meets the more-likely-than-not recognition threshold is initially and subsequently measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized

 

9


Table of Contents

Gemino Healthcare Finance, LLC and Subsidiary

 

Notes to Consolidated Financial Statements

December 31, 2015 and 2014

 

upon settlement with a taxing authority that has full knowledge of all relevant information. The determination of whether or not a tax position has met the more-likely-than-not recognition threshold considers the facts, circumstances, and information available at the reporting date and is subject to management’s judgment. The Company files both federal and state income tax returns; Gemino Funding is a disregarded entity for tax purposes. The Company is no longer subject to examination by taxing authorities for the years before January 1, 2012.

Accounting Standards Update

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) ASU 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”). ASU 2014-09 provides a single comprehensive revenue recognition framework and supersedes existing revenue recognition guidance. Included in the new principles-based revenue recognition model are changes to the basis for deciding on the timing for revenue recognition. In addition, the standard expands and improves revenue disclosures. In August 2015, FASB subsequently issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date which defers the effective date of ASU 2014-09. After the deferral, ASU 2014-09 is effective retroactively for annual or interim reporting periods beginning after December 15, 2018, with early adoption permitted for reporting periods beginning after December 15, 2016. The Company is currently evaluating the impact of adopting ASU 2014-09, but does not expect adoption to have a material effect on the consolidated financial statements.

 

3. Loans Receivable

The following table shows the composition of loans receivable, net as of December 31, 2015 and 2014:

 

     2015      2014  

Revolving loans receivable

   $ 109,717,445       $ 103,428,730   

Term loans receivable

     8,848,056         10,476,042   
  

 

 

    

 

 

 

Total loans receivable

     118,565,501         113,904,772   

Less allowance for loan losses

     (1,194,676      (1,147,891

Less deferred origination fees and costs, net

     (680,872      (531,125

Less discount on loans, net

     —           (23,698
  

 

 

    

 

 

 

Loans receivable, net

   $ 116,689,953       $ 112,202,058   
  

 

 

    

 

 

 

 

10


Table of Contents

Gemino Healthcare Finance, LLC and Subsidiary

 

Notes to Consolidated Financial Statements

December 31, 2015 and 2014

 

4. Allowance for Loan Losses and Recorded Investment in Loans Receivables

The following table summarizes the activity in the allowance for loan losses by loan class for the respective periods ended December 31, 2015 and 2014:

 

   

Beginning
Balance

    Charge-Offs     Recoveries     Provisions     Ending
Balance
    Ending
Balance:
Individually
Evaluated
for
Impairment
    Ending
Balance:
Collectively
Evaluated

for
Impairment
 
    Allowance for Loan Losses - December 31, 2015  

Revolving loans

  $ 1,043,131      $ —        $ 2,227      $ 60,837      $ 1,106,195      $ —        $ 1,106,195   

Term loans

    104,760        —          —          (16,279     88,481        —          88,481   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total

  $  1,147,891      $ —        $ 2,227      $ 44,558      $ 1,194,676      $ —        $ 1,194,676   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 
    Allowance for Loan Losses - December 31, 2014  

Revolving loans

  $ 879,625      $ (407,251   $ —        $ 570,757      $ 1,043,131      $ —        $ 1,043,131   

Term loans

    109,120        —          —          (4,360     104,760        —          104,760   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total

  $ 988,745      $ (407,251   $ —        $ 566,397      $ 1,147,891      $ —        $  1,147,891   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

The following table summarizes the activity in the recorded investment in loans receivable by loan class at December 31, 2015 and 2014:

 

     Ending Balance      Ending
Balance

Individually
Evaluated
for
Impairment
     Ending Balance
Collectively
Evaluated for
Impairment
 
     Loans Receivables - December 31, 2015  

Revolving loans

   $ 109,717,445       $ —         $ 109,717,445   

Term loans

     8,848,056         —           8,848,056   
  

 

 

    

 

 

    

 

 

 

Total

   $ 118,565,501       $ —         $ 118,565,501   
  

 

 

    

 

 

    

 

 

 
     Loans Receivables - December 31, 2014  

Revolving loans

   $ 103,428,730       $ —         $ 103,428,730   

Term loans

     10,476,042         —           10,476,042   
  

 

 

    

 

 

    

 

 

 

Total

   $ 113,904,772       $ —         $ 113,904,772   
  

 

 

    

 

 

    

 

 

 

 

11


Table of Contents

Gemino Healthcare Finance, LLC and Subsidiary

 

Notes to Consolidated Financial Statements

December 31, 2015 and 2014

 

Credit Quality Indicators

The following table summarizes the loan portfolio by the Company’s internal credit rating (scale: 1 to 7) as of December 31, 2015 and 2014: Loans with a rating of 4 or better generally pose minimal risk to the Company as they exhibit, among other things, one or more of the following attributes: (1) well-secured collateral position; (2) satisfactory cash flows; and (3) history of timely payment of debt obligations. Loans credit rated below 4 are considered “Watchlist” loans; an overall degree of risk exists such that management’s review is warranted each quarter.

 

     December 31, 2015  
     Revolving
Loans
     Term Loans  

Rated 4 or better

   $ 98,119,532       $ 8,848,056   

Rated 5

     11,528,246         —     

Rated 6

     69,667         —     
  

 

 

    

 

 

 

Total

   $ 109,717,445       $ 8,848,056   
  

 

 

    

 

 

 
     December 31, 2014  

Rated 4 or better

   $ 96,608,941       $ 10,476,042   

Rated 5

     6,692,397         —     

Rated 6

     127,392         —     
  

 

 

    

 

 

 

Total

   $ 103,428,730       $ 10,476,042   
  

 

 

    

 

 

 

At December 31, 2015 and 2014, the Company had no loans on non-accrual status or loans past due over 90 days still on accrual.

 

5. Furniture and Equipment

Furniture and equipment are comprised of the following at December 31, 2015 and 2014:

 

     2015      2014  

Computer software and equipment

   $ 59,860       $ 48,838   

Furniture and fixtures

     14,731         13,270   

Leasehold improvement

     12,026         12,026   
  

 

 

    

 

 

 

Total

     86,617         74,134   

Less accumulated depreciation

     (60,029      (34,912
  

 

 

    

 

 

 

Furniture and equipment, net

   $ 26,588       $ 39,222   
  

 

 

    

 

 

 

Depreciation expense was $27,657 and $27,576 for the years ended December 31, 2015 and 2014, respectively.

 

6. Debt

The Company entered into a four-year $100,000,000 secured revolving credit facility in September 2013, which is expandable to $150,000,000 under an accordion feature. In March 2014 and June 2014, the credit

 

12


Table of Contents

Gemino Healthcare Finance, LLC and Subsidiary

 

Notes to Consolidated Financial Statements

December 31, 2015 and 2014

 

facility was expanded to $105,000,000 and $110,000,000, respectively. The credit facility matures September 2017 and may be extended upon agreement by all parties. Under the terms of the credit facility, Gemino and Gemino Funding, as applicable, have made certain customary representations and warranties, and are required to comply with various covenants, including financial and reporting requirements and other customary conditions for similar credit facilities. The credit facility also includes customary events of default for credit facilities of this nature.

Under the terms of the credit facility, the lender has agreed to make advances to Gemino Funding, as the issuer, to enable it to purchase eligible loans from Gemino, as the originator and servicer. At December 31, 2015 and 2014, the advances due under the credit facility amounted to $98,500,000 and $95,000,000, respectively. Gemino Funding pledged approximately $119,571,000 and $119,574,000 of eligible loans and related security at December 31, 2015 and 2014, respectively.

Interest on the credit facility accrues at a variable rate per annum of one-month LIBOR plus 2.75% (3.18% and 2.92% at December 31, 2015 and 2014, respectively), payable monthly. The Company also pays customary loan fees for the credit facility.

 

7. Commitments and Concentrations

At December 31, 2015 and 2014, the Company has committed facilities to its borrowers totaling approximately $188,254,000 and $204,926,000, respectively, of which approximately $69,688,000 and $91,021,000, respectively, was unused. Borrowers may borrow up to the lesser of (i) the committed facility or (ii) the underlying collateral value multiplied by the advance rate. Of the unused committed facility amount at December 31, 2015 and 2014, borrowers could borrow up to approximately $20,076,000 and $27,811,000, respectively.

At December 31, 2015 and 2014, the Company had no loans and one loan, respectively, approximating 13% that exceeded 10% of total loans receivable, respectively.

 

8. Lease Commitments

The Company leases its headquarters, regional sales offices and equipment under non-cancelable operating leases, which expire at various dates through 2016. Future lease payments under non-cancelable operating leases are $17,321 for the year ending December 31, 2016. Total rent expense for all leases amounted to approximately $162,000 and $147,000 for the years ended December 31, 2015 and 2014, respectively.

 

9. 401(k) Savings Plan

The Company has a savings incentive plan covering substantially all employees of the Company. Contributions are currently made by the Company in an amount equal to 100% of the first 5% of employee contributions after the employee has completed three months of continued employment. The Company’s contribution for the years ended December 31, 2015 and 2014 was approximately $139,000 and $131,000, respectively.

 

10. Long-Term Incentive Plan

The Company has a Long-Term Incentive Plan (“LTIP Plan”) that provides for an annual bonus pool to employees based on the Company achieving certain performance criteria. For the year ended December 31, 2015, the Company has expensed approximately $131,000 for the LTIP Plan.

 

13


Table of Contents

Gemino Healthcare Finance, LLC and Subsidiary

 

Notes to Consolidated Financial Statements

December 31, 2015 and 2014

 

11. Fair Value Disclosure

Management uses its best judgment in estimating the fair value of the Company’s financial instruments; however, there are inherent weaknesses in any estimation technique. The estimated fair value amounts have been measured as of the Company’s year-end and have not been reevaluated or updated for purposes of these consolidated financial statements subsequent to that date. As such, the estimated fair value of these consolidated financial instruments subsequent to the reporting date may be different than the amounts reported at year-end. These estimates are subjective in nature and include uncertainties and matters of significant judgment and, therefore cannot be determined with precision. Changes in assumptions could significantly affect the estimates. There are three levels of inputs that may be used to measure fair values:

Level 1: Quoted prices (unadjusted) for identical assets or liabilities in active markets that the entity has the ability to access as of the measurement date.

Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

Level 3: Significant unobservable inputs that reflect a company’s own assumptions about the assumptions that market participants would use in pricing an asset or liability.

The following information should not be interpreted as an estimate of the fair value of the entire Company, since a fair value calculation is only provided for a limited portion of the Company’s assets and liabilities. The following methods and assumptions were used to estimate the fair values of the Company’s financial instruments as of December 31, 2015 and 2014:

Cash and cash equivalents – The carrying value approximates fair value for cash and cash equivalents. (Level 1)

Loan receivables, net Fair values for loans are estimated using market interest rates currently being offered for loans with similar terms to borrowers of similar credit quality. (Level 2)

Accrued interest receivable, accrued interest payable – Due to the short-term nature of these amounts, their carrying amounts approximate fair value. (Level 1)

Advances due under credit facility – The fair value of the notes payable is determined from market sources based on current interest rates at the balance sheet date for borrowers with similar credit ratings as the Company. (Level 2)

The estimated fair values of the Company’s financial instruments as of December 31, 2015 and 2014 are as follows:

 

     2015  
     Carrying Value      Fair Value  

Financial assets:

     

Cash and cash equivalents

   $ 6,751,322       $ 6,751,322   

Loan receivables, net

     116,689,953         117,370,825   

Accrued interest receivable

     902,137         902,137   

Financial liabilities:

     

Notes payable

     98,500,000         98,500,000   

Accrued interest payable

     263,185         263,185   

 

14


Table of Contents

Gemino Healthcare Finance, LLC and Subsidiary

 

Notes to Consolidated Financial Statements

December 31, 2015 and 2014

 

 

     2014  

Financial assets:

     

Cash and cash equivalents

   $ 6,339,962       $ 6,339,962   

Loan receivables, net

     112,202,058         112,756,881   

Accrued interest receivable

     884,351         884,351   

Financial liabilities:

     

Notes payable

     95,000,000         95,000,000   

Accrued interest payable

     251,891         251,891   

At December 31, 2015 and 2014, the Company had no financial assets or liabilities measured at fair value on a nonrecurring basis.

 

12. Contingencies

In August 2012, the Company agreed to indemnify the buyer of a distressed business to which the Company had provided a loan. The agreement provides an indemnification up to $4.5 million for acts of gross negligence or willful misconduct by the prior operators of the business, and has no expiration. In addition, the agreement provided a limited indemnification for any breaches of customary representations and warranties related to the transaction, which expired in August 2014. The former members of the Company (“Sellers”) (Note 1) who sold their equity interests to Solar have agreed to indemnify the Company for any related losses. The Company received a claim from the buyer relating to the breaches of customary representations and warranties indemnification, which it is disputing, and believes the range of reasonably possible amounts is not material to the consolidated financial statements. Additionally, this claim is fully covered by a Sellers’ indemnification escrow account. The Company believes it is unlikely that any additional claims will be made by the buyer and, therefore, no liability has been recorded for these contingencies. In the event the Company’s assumptions used to evaluate this matter change in future periods, it may be required to record a liability to reflect a potential adverse outcome.

 

13. Subsequent Events

The Company evaluated subsequent events for recognition or disclosure through February 12, 2016, which was the date the consolidated financial statements were available to be issued.

 

15